Commentary & Opinion
Opinion Piece, Editorial React to Lancet Article on WHO, Global Fund and Malaria Treatment
January 21, 2004
If the Global Fund to Fight AIDS, Tuberculosis and Malaria cannot "get it right" in its policy on malaria drugs, as suggested by a recent article in the Lancet, "one wonders if it can sustain decent AIDS treatment," Richard Tren, director of Africa Fighting Malaria, and Roger Bate, a visiting fellow at the American Enterprise Institute, write in a Washington Times opinion piece. The authors of the Lancet article -- a "who's who of the malaria research world" -- attribute rising malaria rates to the World Health Organization's "policy failure[s]" and to the Global Fund's funding the purchase of "ineffective drugs," Tren and Bate say. Although both WHO and the Global Fund seem "loathe to buy patented drugs, whether for malaria control or AIDS ... buying off-patent drugs that don't work is unacceptable," Tren and Bate say. In addition, "AIDS activists and Democrats" who criticize Bush for his "miserly funding" of WHO and the Global Fund should concede that Bush is "right to retain control" of foreign aid because it is "far from certain" that the agencies "can be trusted," Tren and Bate say, concluding that Bush and African health ministers should "take the health bureaucrats" of WHO and the Global Fund "to task" over their "negligent [malaria] policies" (Tren/Bate, Washington Times, 1/19).
Bush Administration Should "Reconsider" Funding
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.